QNTM - רווח נקי למניה (EPS TTM) Quantum BioPharma Ltd.
Quantum BioPharma Ltd (QNTM) develops orphan disease medications through partnerships with biotech laboratories. Rolling trailing twelve-month net income per share demonstrates current financial stability, and this metric has reached the level of -5.68. Revenues are based on royalties from inflammation therapy patents, however, frequent strategic shifts between AI and cannabinoids weaken the company's competitive advantages.
פילוחים אנליטיים של חברת Quantum BioPharma Ltd
The operational efficiency of Quantum BioPharma Ltd (QNTM) is reflected in the current annual net earnings per share. This indicator captures the balance between the issuer's production capacity and market demand over a rolling year. The calculated value of -5.68 determines the real return on each share of capital, adjusted for dilution. Amidst saturation in the biotechnology market, this metric assesses the success of diversification into the sleep therapy segment. The stability of this figure confirms the resilience of the company's assets.
